---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Special populations"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Special populations. Topics: Age range of the pivotal cohort: females aged 6 to under 22 years, Children aged 5 to 8 years: REVEAL Pediatric trial, Children aged over 2 to under 4 years: ASPIRE trial, Extrapolation of efficacy to children aged 2 to under 6 years, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/special-populations"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Age range of the pivotal cohort: females aged 6 to under 22 years

> “Females between the ages of 12 and <22 in Part A (closed) and females between the ages of 6 and <22 in Part B (pivotal cohort).”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.8-2"></a>

### Children aged 5 to 8 years: REVEAL Pediatric trial

> “Participant is between ≥5 to ≤8 years of age at the time of consent.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-2.1.2.8-3"></a>

### Children aged over 2 to under 4 years: ASPIRE trial

> “Pediatric females between the ages of 2 and less than 4 years old.”
> “The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-2.1.2.8-4"></a>

### Extrapolation of efficacy to children aged 2 to under 6 years

> “A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.8-5"></a>

### Paediatric subsets and studies agreed in the European Union paediatric investigation plan

> “From birth to less than 18 years of age”
> “Open-label, randomized, 2-part study including a dose-escalation (Part A) and dose expansion (Part B) to evaluate the safety, efficacy, and durability of a single intrathecal dose of TSHA-102 in female children from 2 to less than 9 years of age with Rett syndrome with a documented MECP2 loss-of-function gene mutation.”
> “Deferral for one or more measures contained in the paediatric investigation plan: Yes”
> “Date of completion of the paediatric investigation plan: By December 2033”

Source: [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)

<a id="topic-2.1.2.8-6"></a>

### Sex: the trials enrolled females

> “The REVEAL Pivotal Trial is a single-arm, open-label study evaluating the efficacy and safety of TSHA-102 in females with Rett syndrome, with each patient serving as their own control.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

> “Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.8-7"></a>

### Participants requiring invasive ventilatory support were excluded

> “Participant requires invasive ventilatory support.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

> “Participant requires non-invasive and invasive ventilatory support.”
> “Participant has acute or chronic hepatitis B or C infections.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-2.1.2.8-8"></a>

### Pregnancy, lactation, renal impairment, and hepatic impairment

No evidence found.

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
